Narrative
Over a billion people worldwide are affected by serious fungal disease, resulting in over 1.5 million deaths annually. Our research led an evidence-based global advocacy programme to address lack of diagnostics and generic antifungals as well as inadequate clinical skills. Denning set up the Global Action Fund for Fungal Infections (GAFFI) in 2013 to mitigate the global impact of fungal diseases. Five antifungal drugs and eight key diagnostics are now flagged by the World Health Organization (WHO) as ‘Essential’, and GAFFI has produced estimates of fungal diseases for 65 countries. National clinical training programmes in Guatemala and Nigeria for HIV patients with life-threatening fungal infections resulted in improved clinical skills and saved lives.Impact date | 1 Aug 2013 → 31 Dec 2020 |
---|---|
Category of impact | Health and wellbeing |
Impact level | Adoption |
Research Beacons, Institutes and Platforms
- Global inequalities
- Lydia Becker Institute
- Global Development Institute
Documents & Links
Related content
-
Research output
-
Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized
Research output: Contribution to journal › Article › peer-review
-
Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis
Research output: Contribution to journal › Article › peer-review
-
Global burden of chronic pulmonary aspergillosis as a sequel to tuberculosis.
Research output: Contribution to journal › Article › peer-review
-
Global and Multi-National Prevalence of Fungal Diseases – Estimate Precision
Research output: Contribution to journal › Article › peer-review
-
Global access to antifungal therapy and its variable cost
Research output: Contribution to journal › Article › peer-review
-
The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala
Research output: Contribution to journal › Article › peer-review
-
Impacts
-
Defining global antifungal azole resistance in Aspergillus – enhancing diagnostics and driving drug discovery
Impact: Health and wellbeing, Policy, Economic
-
Transforming patient outcome of pulmonary aspergillosis with better and faster diagnosis and therapy
Impact: Health and wellbeing, Economic
-
Diagnostics and novel life-saving therapies for aspergillosis
Impact: Health impacts
-
Projects